ChemInform Abstract: Ligustrazine Derivatives. Part 5. Design, Synthesis and Biological Evaluation of Novel Ligustrazinyloxy‐Cinnamic Acid Derivatives as Potent Cardiovascular Agents.

hongfei chen,guoning li,peng zhan,xinyong liu

DOI: https://doi.org/10.1002/chin.201212176

2012-01-01

ChemInform

Abstract:Abstract Compound (VIIIa) is found to be the most active anti‐platelet agent.

What problem does this paper attempt to address?

Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.

Hongfei Chen,Guoning Li,Peng Zhan,Xinyong Liu

DOI: https://doi.org/10.1016/j.ejmech.2011.09.030

IF: 7.088

2011-01-01

European Journal of Medicinal Chemistry

Abstract:A series of novel ligustrazinyloxy-cinnamic acid derivatives were designed, synthesized and evaluated for their inhibitory effect on adenosine diphosphate (ADP)-induced platelet aggregation in vitro, and also assayed for their protective effect against hydrogen peroxide (H2O2)-induced oxidative damage on ECV-304 cells. Some compounds exhibited high activity in one or both of the assays, of which, compound 2e displayed the highest protective effect on the proliferation of the damaged ECV-304 cells (EC50=0.020mM), and compound 2f was the most active anti-platelet aggregation agent (EC50=0.054mM). Structure–activity relationships were briefly discussed.
Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides As Cardiovascular Agents

Zhenyu Li,Fang Yu,Lei Cui,Wenmin Chen,Shouxun Wang,Peng Zhan,Yuemao Shen,Xinyong Liu

DOI: https://doi.org/10.2174/157340641130900042

2013-01-01

Medicinal Chemistry

Abstract:A series of novel Ligustrazinyl amides was designed, synthesized and evaluated for their protective effect on the injured vascular endothelial cells. The preliminary results demonstrated that some compounds possessed more potent activities than that of Ligustrazine in stimulating replication of the injured human umbilical vascular endothelial cells (HUVECs) that is damaged by hydrogen peroxide. Among the active compounds, compounds 8i, 8t and 8u exhibited the highest potency with low EC50 values of 0.037, 0.070 and 0.055 mM, respectively. Structure-activity relationships were briefly discussed.
Ligustrazine derivatives. Part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents.

Xian-Chao Cheng,Xin-Yong Liu,Wen-Fang Xu,Xiu-Li Guo,Ning Zhang,Yu-Ning Song

DOI: https://doi.org/10.1016/j.bmc.2009.03.012

IF: 3.461

2009-01-01

Bioorganic & Medicinal Chemistry

Abstract:A series of novel acylpiperazinyl Ligustrazine derivatives was designed and synthesized. Their protective effects on damaged ECV-304 cells and antiplatelet aggregation activities were reported.
Ligustrazine derivatives. Part 6: design, synthesis and evaluation of novel ligustrazinyl acylguanidine derivatives as potential cardiovascular agents.

Zhenyu Li,Fang Yu,Lei Cui,Peng Zhan,Shouxun Wang,Yuemao Shen,Xinyong Liu

DOI: https://doi.org/10.2174/157340612802084243

2012-01-01

Medicinal Chemistry

Abstract:A series of novel Ligustrazinyl acylguanidines was designed, synthesized and evaluated for their protective effect on injured vascular endothelial cell (ECV-304). The preliminary results demonstrated that some compounds possessed more potent activities than that of Ligustrazine in stimulating replication of the injured endothelial cell. Among the active compounds, compounds 8b, 8f and 8l displayed remarkable antioxidative activity with low EC50 values of 0.097, 0.059 and 0.094 mM, respectively. Structure-activity relationships were briefly discussed.
Ligustrazine Derivatives. Part 4: Design, Synthesis, and Biological Evaluation of Novel Ligustrazine-Based Stilbene Derivatives As Potential Cardiovascular Agents

Lijuan Deng,Xiuli Guo,Li Zhai,Yuning Song,Hongfei Chen,Peng Zhan,Jingde Wu,Xinyong Liu

DOI: https://doi.org/10.1111/j.1747-0285.2012.01332.x

2012-01-01

Chemical Biology & Drug Design

Abstract:A series of novel stilbene derivatives containing ligustrazinyl moiety was designed, synthesized, and assayed for their protective effects on damaged endothelial cells. The results showed that most ligustrazinyl stilbene derivatives exhibited high protective effects on the human umbilical vascular endothelial cells (HUVECs) damaged by hydrogen peroxide in comparison with Ligustrazine. The stilbene derivatives A6, A9, A11, A21, A24, A25, and A27 exhibited high potency with low EC50 values ranged from 0.0249 μm to 0.0898 mm. Compound A27 displayed EC50 0.0249 μm, which is 30 000 times higher than that of Ligustrazine, presenting a most promising lead for further investigation. Structure–activity relationships were briefly discussed.
Design, Synthesis, and Biological Activities of Novel Ligustrazine Derivatives.

Xian-Chao Cheng,Xin-Yong Liu,Wen-Fang Xu,Xiu-Li Guo,Yang Ou

DOI: https://doi.org/10.1016/j.bmc.2007.03.033

IF: 3.461

2007-01-01

Bioorganic & Medicinal Chemistry

Abstract:A series of novel Ligustrazine derivatives was designed, synthesized, and assayed for their protective effects on damaged ECV-304 cells and antiplatelet aggregation activities. The results showed that most Ligustrazine derivatives exhibited lower EC50 values for protective effects on the ECV-304 cells damaged by hydrogen peroxide in comparison with Ligustrazine. And some Ligustrazine derivatives presented better antiplatelet aggregation activities than Ligustrazine. The derivatives containing the bisphenylmethyl pharmacophore (7a-c) exhibited highest potency. Compound 7a displayed most potential protective effects on the ECV-304 cells damaged by hydrogen peroxide, and compound 7c was found to be the most active antiplatelet aggregation agent. Structure-activity relationships were briefly discussed. (c) 2007 Elsevier Ltd. All rights reserved.
Recent Advances in the Structural Modification of Ligustrazine and Cerebro/Cardiovascular Activity of Ligustrazine Derivatives

XC Cheng,XY Liu,WF Xu

DOI: https://doi.org/10.1358/dof.2005.030.10.927377

2005-01-01

Drugs of the Future

Abstract:Recent advances in the structural modification of ligustrazine and studies on the bioactivities of ligustrazine derivatives are reviewed in this article. Due to its rapid metabolism and short half-life, ligustrazine is not suitable for application in clinical practice. Derivatives of ligustrazine were therefore designed and synthesized, including ether, amine, amide, hydrocarbon and deuterated derivatives of ligustrazine and ester and alcohol derivatives of 2-hydroxymethyl-3,5,6-trimethylpyrazine, an active metabolite of ligustrazine. Some of these compounds present better cerebro- arid cardiovascular activities and more favorable pharmacokinetic properties compared to the parent compound.
Synthesis of Novel Ligustrazine Derivatives As Potential Platelet Aggregation Inhibitors

Xian Chao Cheng,Xin Yong Liu,Wen Fang Xu

2006-01-01

Abstract:A series of novel ligustrazine derivatives were synthesized. These compounds have not been reported in literature, and their chemical structures were confirmed by IR, H-1 NMR and ESI-MS. The preliminary antiplatelet aggregation screening results demonstrated that the compounds 7a, 7b and 7c showed higher potency than ligustrazine.
The Preparation of Novel Ligustrazine Derivatives As Potential Cerebrocardiac Vascular Agents.

Xian-chao Cheng,Xin-yong Liu,Wen-fang Xu

DOI: https://doi.org/10.1002/chin.200703204

2006-01-01

Journal of Chemical Research

Abstract:A series of novel substituted cinnamoylpiperazinyl ligustrazine derivatives 7 has been prepared by alkylation of cinnamoylpiperazines by (chloromethyl)trimethylpyrazine (5) or by cinnamoylation of trimethyl(piperazinomethyl) pyrazine (6).
Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives

Jinmi Zou,Ping Gao,Xia Hao,Haoran Xu,Peng Zhan,Xinyong Liu

DOI: https://doi.org/10.1016/j.ejmech.2018.01.097

IF: 7.088

2018-01-01

European Journal of Medicinal Chemistry

Abstract:Ligustrazine is a main active fraction of the traditional medicine known as Ligusticum chuanxiong hort, which has been used as clinical medication for cerebral thrombosis, coronary heart disease and stenocardia recently. The rapid metabolism and short half-life of ligustrazine seriously limits its application in clinical practice. Therefore, derivatives of ligustrazine are designed and synthesized in our and other labs, including piperazine, cinnamic acid, styrene, acylguanidine, amides, curcumin and triterpenes derivatives of ligustrazine. Most of these compounds present better pharmacodynamics activities and more favorable pharmacokinetic properties compared to the parent compound. Besides, some new biological activities of these compounds are discovered. Hence, this review continues the previous review of our group as well as aims to highlight recent prominent advances in this field in the past ten years.
Synthesis Of Ligustrazine-Aromatic Acid Derivatives And Their Inhibitory Effect On Platelet Aggregation

Jia-Ming Li,Yong-Hai Zhao,Feng-Shi Ma,Zhi-Yong Wang,Yong He,De-Shuai Zhang,Hai-Bo Ren

2008-01-01

Chinese Journal of Organic Chemistry

Abstract:Ligustrazine and ferulic acid, which are useful compounds of Chinese traditional medicine, were used as leading compounds. Six ligustrazine-aromatic acid derivatives were designed and synthesized based on the twin drug principle. Their structures were characterized by IR, H-1 NMR, C-13 NMR and mass spectra. In the in vivo experiment, some compounds have significant inhibitory effect on adenosine diphosphate (ADP) induced platelet aggregation. Among them, the inhibitory effect of compound 1a was 5.7 times than ozagrel.
Structural Modification of Ligustrazine

CHENG Xian-chao,LIU Xin-yong,XU Wen-fang

DOI: https://doi.org/10.3969/j.issn.1001-5094.2005.06.001

2005-01-01

Abstract:The recent advances in structural modification of Ligustrazine and bioactivities of Ligustrazine derivatives were reviewed in this article. In view of the rapid metabolism and short half-life, Ligustrazine is not suitable to be applicated in clinical practice. Some leading drugs of Ligustrazine were designed and synthesized, such as the ether, amine, hydrocarbon and deuterated derivatives from Ligustrazine and the ester and alcohol derivatives from 2-hydroxymethyl-3,5,6-trimethyl pyrazine, one active metabolite of Ligustrazine. Some of them present better cerebrocardiac vascular activities and favorable pharmacokinetic properties than Ligustrazine.
Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents

Hongfei Chen,Guoning Li,Peng Zhan,Xiuli Guo,Qian Ding,Shouxun Wang,Xinyong Liu

DOI: https://doi.org/10.1039/c3md20352b

2013-01-01

MedChemComm

Abstract:A series of novel ligustrazinylated derivatives was designed, synthesized and evaluated for their protective effects against hydrogen peroxide (H2O2)-induced oxidative damage on ECV-304 cells, and also assayed for their inhibition effects on platelet aggregation induced by adenosine diphosphate (ADP). Biological results showed that some compounds exhibited moderate to potent activities in one or both of the assays. Among these compounds, compound 3 displayed the highest protective effect on the damaged ECV-304 cells with EC50 = 0.0040 mM, and compound 1c was the most active platelet aggregation inhibitor (EC50 = 0.40 mM). Structure-activity relationships were briefly discussed.
Synthesis and Evaluation of Novel Nitric Oxide-Donating Ligustrazine Derivatives as Potent Antiplatelet Aggregation Agents

Han-Xu Li,Jian-Hui Tian,Hua-Yu Li,Xin Wan,Yu Zou

DOI: https://doi.org/10.3390/molecules28083355

IF: 4.6

2023-04-12

Molecules

Abstract:Antiplatelet aggregation agents have demonstrated clinical benefits in the treatment of ischemic stroke. In our study, a series of novel nitric oxide (NO)-donating ligustrazine derivatives were designed and synthesized as antiplatelet aggregation agents. They were evaluated for the inhibitory effect on 5′-diphosphate (ADP)-induced and arachidonic acid (AA)-induced platelet aggregation in vitro. The results showed that compound 15d displayed the best activity in both ADP-induced and AA-induced assays, and compound 14a also showed quite better activity than ligustrazine. The preliminary structure-activity relationships of these novel NO-donating ligustrazine derivatives were discussed. Moreover, these compounds were docked with the thromboxane A2 receptor to study the structure-activity relationships. These results suggested that the novel NO-donating ligustrazine derivatives 14a and 15d deserve further study as potent antiplatelet aggregation agents.

chemistry, multidisciplinary,biochemistry & molecular biology
Design, Synthesis and Biological Evaluation of Novel Trimethylpyrazine-2-carbonyloxy-cinnamic Acids As Potent Cardiovascular Agents

Hongfei Chen,Guoning Li,Peng Zhan,Hong Li,Shouxun Wang,Xinyong Liu

DOI: https://doi.org/10.1039/c4md00022f

2014-01-01

MedChemComm

Abstract:A series of novel trimethylpyrazine-2-carbonyloxy-cinnamic acids and esters were designed, synthesized and evaluated for their inhibitory effect on adenosine diphosphate (ADP)-induced platelet aggregation in vitro and also assayed for their protective effect against hydrogen peroxide (H2O2)-induced oxidative damage on Ea.hy926 cells. The results showed that many compounds exhibited high activity in one or both of the assays, of which, compound F′10 displayed the highest protective effect on the proliferation of the damaged Ea.hy926 cells (EC50 = 1.7 μM), presenting almost 40 times higher potency than that of lipoic acid, and compound F3 was the most active anti-platelet aggregation agent with IC50 = 9.6 μM, comparable to that of clopidogrel. The structure–activity relationships of these compounds were also discussed.
Synthesis and Biological Evaluation of New Ligustrazine Derivatives As Anti-Tumor Agents

Penglong Wang,Gaimei She,Yanan Yang,Qiang Li,Honggui Zhang,Jie Liu,Yinqiu Cao,Xin Xu,Haimin Lei

DOI: https://doi.org/10.3390/molecules17054972

IF: 4.6

2012-01-01

Molecules

Abstract:To discover new anti-cancer agents with multi-effect and low toxicity, a series of ligustrazine derivatives were synthesized using several effective anti-tumor ingredients of Shiquandabu Wan as starting materials. Our idea was enlightened by the “combination principle” in drug discovery. The ligustrazine derivatives’ anti-tumor activities were evaluated on the HCT-8, Bel-7402, BGC-823, A-549 and A2780 human cancer cell lines. In addition the angiogenesis activities were valued by the chick chorioallantoic membrane (CAM) assay. 1,7-bis(4-(3,5,6-Trimethylpyrazin-2-yl)-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (4) and 3 α,12 α-dihydroxy-5β-dholanic acid-3,5,6-trimethylpyrazin-2-methyl ester (5) not only displayed antiproliferative activities on these cancer cells, but also dramatically suppressed normal angiogenesis in CAM. The LD50 value of the compound 5 exceeded 3.0 g/kg by oral administration in mice.
Synthesis and NHE1 Inhibitory Activity of Ligustrazine Derivatives

Mei Ren,Yun Gen Xu,Na Wen,Da Yong Zhang,Wei Yi Hua

DOI: https://doi.org/10.1016/j.cclet.2007.03.020

2007-01-01

Abstract:A series of novel derivatives of ligustrazine linked with substituted benzoyl guanidine were synthesized. These compounds have not been reported in literature, and their chemical structures were confirmed by IR, 1H NMR and MS. The results of NHE1 inhibitory activity test showed that compounds I2, I3, I4, I6, and I7 possess more potent NHE1 inhibitory activity than cariporide.
Design of Novel Thiazole Bearing Pyrazole Derivatives and Their Dual Activities as ACE Inhibitors and Calcium Channel Blockers in Cardiovascular Disease

Cheng Jiang,Zhi Yuan,Ju-Fei Wang,Jie Fu,Guang-Jun Jiang,Liang-Rong Zheng

2016-01-01

Latin american journal of pharmacy

Abstract:In an attempt to develop drugs for cardio-vascular disease, present manuscript deal with the development of dual acting agents targeting angiotensin converting enzyme (ACE) and calcium channel to treat hypertension. These molecules were developed via efficient multi-step synthetic route in excellent yield. In ACE inhibitors assay, these compounds showed considerable percentage of inhibition (32-94 %) with IC50 = 1.2 and 1.5 mu M for most promising compound 6e and 6o, respectively. In molecular docking study with ACE, compound 6e revealed similar fashion of molecular interaction with catalytic residues His353, Ala 354, Tyr 523, Tyr 520, and Glu 152, comparable with standard lisinopril. Additionally, in rat aortic strip model, these molecules significantly induce vasorelaxaticin via inhibiting Ca2+ channel in dose dependent manner.
Chuanxiongdiolides R4 and R5, phthalide dimers with a complex polycyclic skeleton from the aerial parts of Ligusticum chuanxiong and their vasodilator activity

Fei Tang,Yong-Ming Yan,Hong-Ling Yan,Li-Xia Wang,Chang-Jiang Hu,Hong-Liang Wang,Hui Ao,Cheng Peng,Yu-Zhu Tan

DOI: https://doi.org/10.1016/j.bioorg.2020.104523

IF: 5.307

2021-02-01

Bioorganic Chemistry

Abstract:Chuanxiongdiolides R4-R6 (1–3), three novel phthalide dimers featuring two classes of unreported monomeric units (ligustilide/senkyunolide A and ligustilide/neocnidilide) with an unprecedented linkage style (3a,7′/7a,7′a), were isolated from the aerial parts of Ligusticum chuanxiong, together with three pairs of enantiomeric phthalide dimers [(−)/(+)-4a/4b, 5a/5b, and 6a/6b]. The bioassays revealed that compounds 1, 3, 4, 5, and 6 showed significant vasodilation effects, and the mechanism may be attributed to Cav1.2 activation blockade. Based on the established compounds library, the structure activity relationship of the phthalides was proposed. Our findings afford possible leads for developing new vasodilator against cardiovascular and cerebrovascular diseases such as hypertension and ischemic stroke.

biochemistry & molecular biology,chemistry, organic
Research Progress on Pharmacological Effects of Ligustrazine - Ferulic Acid Derivatives

WANG Zhen,LIU Xin-yong,WANG Jing,CHEN Hong-fei,MA Chen-chen

DOI: https://doi.org/10.3969/j.issn.1672-7738.2011.11.020

2011-01-01

Abstract:In this paper the pharmacological effects of ligustrazine and ferulic acid were introduced,which were active ingredients of chuanxiong.Also the structural modification of ligustrazine-ferulic acid derivatives based on the structure of ligustrazine and ferulic acid as nucleus and combination principle were reviewed to provide reference for the finding of compounds with high activity.

ChemInform Abstract: Ligustrazine Derivatives. Part 5. Design, Synthesis and Biological Evaluation of Novel Ligustrazinyloxy‐Cinnamic Acid Derivatives as Potent Cardiovascular Agents.

Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.

Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides As Cardiovascular Agents

Ligustrazine derivatives. Part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents.

Ligustrazine derivatives. Part 6: design, synthesis and evaluation of novel ligustrazinyl acylguanidine derivatives as potential cardiovascular agents.

Ligustrazine Derivatives. Part 4: Design, Synthesis, and Biological Evaluation of Novel Ligustrazine-Based Stilbene Derivatives As Potential Cardiovascular Agents

Design, Synthesis, and Biological Activities of Novel Ligustrazine Derivatives.

Recent Advances in the Structural Modification of Ligustrazine and Cerebro/Cardiovascular Activity of Ligustrazine Derivatives

Synthesis of Novel Ligustrazine Derivatives As Potential Platelet Aggregation Inhibitors

The Preparation of Novel Ligustrazine Derivatives As Potential Cerebrocardiac Vascular Agents.

Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives

Synthesis Of Ligustrazine-Aromatic Acid Derivatives And Their Inhibitory Effect On Platelet Aggregation

Structural Modification of Ligustrazine

Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents

Synthesis and Evaluation of Novel Nitric Oxide-Donating Ligustrazine Derivatives as Potent Antiplatelet Aggregation Agents

Design, Synthesis and Biological Evaluation of Novel Trimethylpyrazine-2-carbonyloxy-cinnamic Acids As Potent Cardiovascular Agents

Synthesis and Biological Evaluation of New Ligustrazine Derivatives As Anti-Tumor Agents

Synthesis and NHE1 Inhibitory Activity of Ligustrazine Derivatives

Design of Novel Thiazole Bearing Pyrazole Derivatives and Their Dual Activities as ACE Inhibitors and Calcium Channel Blockers in Cardiovascular Disease

Chuanxiongdiolides R4 and R5, phthalide dimers with a complex polycyclic skeleton from the aerial parts of Ligusticum chuanxiong and their vasodilator activity

Research Progress on Pharmacological Effects of Ligustrazine - Ferulic Acid Derivatives